4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-25-286218
Chief Executive Officer sold 10,916 shares at an average $25.20 ($275,047)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham Chief Executive Officer | 2025-11-17 | Sale 10b5-1 | −2,777 | $24.92 | $69,216 | 576,802 | D: show line 1 in the form |
| Ceesay Abraham Chief Executive Officer | 2025-11-17 | Sale 10b5-1 | −3,056 | $25.43 | $77,715 | 573,746 | D: show line 2 in the form |
| Ceesay Abraham Chief Executive Officer | 2025-11-17 | Sale 10b5-1 | −2,242 | $24.91 | $55,850 | 38,819 | I: show line 3 in the form |
| Ceesay Abraham Chief Executive Officer | 2025-11-17 | Sale 10b5-1 | −2,841 | $25.44 | $72,267 | 35,978 | I: show line 4 in the form |
| Open-market sales · 10,916 sh · avg $25.20 · $275,047 | |||||||
Loading xslF345X05/ownership.xml…